An informational resource for healthcare professionals interested in stroke reduction, venous protection, and vascular protection. Stay current on relevant clinical information and guidelines, advocacy initiatives, policy updates, latest news, and events through the many resources found in the tabs listed here.
Educational resources about reducing stroke by understanding the underlying thrombotic risk in patients with or without atrial fibrillation.
Educational resources about the underlying thrombotic risk of major adverse cardiac events in patients with vascular diseases such as Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), and Heart Failure.
While we in the medical community can appropriately pat ourselves on the back for winning numerous battles, the war on atherosclerosis is not over. We have not cured atherosclerosis.
The burden of peripheral artery disease is shifting rapidly from high-income to low-income and middle-income countries. This article examines the epidemiology of PAD and, where feasible, takes a global perspective.
This resource identifies the signs and symptoms of peripheral artery disease and distinguishes them from other diseases that can mimic PAD. Diagnose PAD using the history, findings on physical examination, and ankle brachial index, and formulate an integrated treatment program to improve the symptoms and quality of life and decrease the high cardiovascular event rate.
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.
Focusing on the Most Devastating Diseases of Our Lifetime
We want to drive down the rates of cardiovascular and metabolic diseases with our science, innovation, and solutions. We are already transforming the treatment of type 2 diabetes and thrombosis with our products. And while these important products continue to change the way doctors are treating diabetes and thrombosis, we are also focused on finding the next wave of transformational treatments for cardiovascular and metabolic diseases that will prevent, intercept, and cure devastating diseases.